3616-57-7

Usage

Chemical Properties

CLEAR YELLOW TO BROWN LIQUID

InChI:InChI=1/C10H23NO2/c1-5-11(6-2)9-10(12-7-3)13-8-4/h10H,5-9H2,1-4H3/p+1

Upstream product

• 109-89-7 diethylamine 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 64-17-5 ethanol 
• 121-44-8 triethylamine 
• 621-62-5 chloroacetaldehyde diethyl acetal 

Downstream Products

• 123367-22-6 (E)-N,N-dimethyl-2-(4-nitro-1-oxidopyridin-3-yl)ethenamine 
• 98398-26-6 diethyl-(2,2-diphenyl-ethyl)-amine 

Relevant academic research and scientific papers

Preparation method of novel quinazoline drug side chain

The invention discloses a preparation method of a novel quinazoline drug side chain, which comprises the following steps: taking bromoacetaldehyde diethyl acetal and diethylamine as raw materials, carrying out condensation reaction, extracting, drying, concentrating, rectifying and the like to obtain a condensation compound, and hydrolyzing, extracting and concentrating the condensation compound to obtain 2-diethyl amino acetaldehyde. The raw materials are cheap and easy to obtain, the reaction condition is mild, the operation is safe and simple, the product quality is good, and industrial production is facilitated.

Iodine-catalyzed oxidative rearrangement of amines to a-amino acetals and a-amino aldehydes

A protocol for iodine-catalyzed oxidative rearrangement of tertiary and secondary amines has been developed. This metal-free protocol provides an atom-economical, efficient access to synthetically useful a-amino acid derivatives from readily available acyclic and cyclic tertiary or secondary amines.

Iodine-Catalyzed Oxidative Rearrangement of Amines to α-Amino Acetals and α-Amino Aldehydes

A protocol for iodine-catalyzed oxidative rearrangement of tertiary and secondary amines has been developed. This metal-free protocol provides an atom-economical, efficient access to synthetically useful α-amino acid derivatives from readily available acyclic and cyclic tertiary or secondary amines. (Figure presented.).

SUBSTITUTED AMINOQUINAZOLINES USEFUL AS KINASES INHIBITORS

The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.